This episode of "This Week in Virology" examines the intersection of politics, cutting-edge pharmacology, and cancer research. The hosts begin by dissecting two recent political developments in the US: a new Executive Order that places federal grantmaking under the review of political appointees, which they condemn as an ideological "war on science," and the HHS decision, under RFK Jr., to wind down mRNA vaccine development, a move they decry as based on dangerous falsehoods. The discussion then shifts to science, first covering Lenacapavir, a revolutionary HIV capsid inhibitor. This drug's extreme potency and long half-life allow for a twice-yearly injection regimen for pre-exposure prophylaxis (PrEP), though its high price from Gilead sparks criticism. Finally, the team delves into a recent Nature paper revealing how respiratory viral infections like influenza and SARS-CoV-2 can "awaken" dormant metastatic breast cancer cells in the lungs. They explain the complex immunological mechanism, involving an initial IL-6 trigger and subsequent CD4 T-cell suppression of anti-tumor CD8 T-cells, and discuss supporting evidence from human data collected during the COVID-19 pandemic.
TWiV 1243: Analyzing the Intersection of Politics, Virology, and Cancer
2:35 A "Vicious" Executive Order on Grant Oversight: The hosts discuss a new executive order, "Improving Oversight of Federal Grant Making," arguing its true purpose is to subject scientific grants to approval by political appointees. They view this as a blatant attempt to inject far-right ideology into the research process, which will harm science, delay funding, and hurt the US economy.
10:34 HHS Halts mRNA Vaccine Development: The podcast covers the announcement from HHS, led by RFK Jr., terminating 22 mRNA vaccine development programs based on the claim that they are ineffective. The hosts call this justification a "bloody lie," citing evidence that these vaccines saved millions of lives, and frame the decision as a dangerous victory for the anti-vaccine movement that is manufacturing a future health crisis.
17:21 Lenacapavir: A "Game-Changing" HIV Drug: The hosts detail the science behind Lenacapavir, a first-in-class HIV capsid inhibitor. It is exceptionally potent (active in the picomolar range) and has a very long half-life, making it a revolutionary drug for both treatment and prevention.
19:01 Twice-Yearly HIV Prevention: A key benefit of Lenacapavir is its use for pre-exposure prophylaxis (PrEP). Given subcutaneously, it requires only two injections per year to prevent infection, a massive improvement over daily pills. Clinical trials have shown near-100% effectiveness.
41:00 The High Cost of a Cure: Despite its breakthrough potential, the pharmaceutical company Gilead has priced Lenacapavir at $28,000 per year. The hosts criticize this as price gouging, noting that UNAIDS estimates it could be produced for as little as $40 per year, making it inaccessible for those who need it most.
45:54 How Viruses Can "Awaken" Dormant Cancer: The discussion turns to a Nature paper showing that respiratory viral infections like influenza and SARS-CoV-2 can reactivate dormant disseminated cancer cells (DCCs) from breast cancer that reside in the lungs. This provides a potential mechanism for the increased cancer mortality observed during the COVID-19 pandemic.
1:02:29 A Complex Immune Response Gone Wrong: The paper proposes a two-stage mechanism for this reawakening. First, the inflammatory cytokine IL-6, produced during the viral infection, acts as an "alarm clock" to trigger the dormant cells. Second, CD4 T-cells are reprogrammed to create niches that suppress the anti-tumor activity of killer CD8 T-cells, allowing the cancer to persist and grow.
1:16:36 Pandemic Data Supports the Findings: The mouse model findings are supported by human observational studies. Analysis of data from the UK Biobank and other databases showed that cancer survivors who contracted SARS-CoV-2 (before vaccines) had a significantly higher risk of all-cause mortality and progression to metastatic disease.
1:28:10 Potential Interventions and Future Questions: The hosts conclude by discussing potential interventions, such as anti-IL-6 therapies, for cancer survivors with respiratory infections. They also raise important questions about whether vaccination could be protective by preventing severe disease or if it carries any risk itself.